CU20150066A7 - Compuestos tricíclicos para inhibir el canal cftr - Google Patents

Compuestos tricíclicos para inhibir el canal cftr

Info

Publication number
CU20150066A7
CU20150066A7 CUP2015000066A CU20150066A CU20150066A7 CU 20150066 A7 CU20150066 A7 CU 20150066A7 CU P2015000066 A CUP2015000066 A CU P2015000066A CU 20150066 A CU20150066 A CU 20150066A CU 20150066 A7 CU20150066 A7 CU 20150066A7
Authority
CU
Cuba
Prior art keywords
pharmaceutically acceptable
tricyclic compounds
cftr channel
inhibit
acceptable salt
Prior art date
Application number
CUP2015000066A
Other languages
English (en)
Inventor
Mahbub Ahmed
Alexander Ashall-Kelly
Louisa Gueritz
Jeffrey Mckenna
Joseph Mckenna
Simon Mutton
Rakesh Parmar
Jon Shepherd
Paul Wright
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030372&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20150066(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20150066A7 publication Critical patent/CU20150066A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención proporciona compuestos tricíclicos heterocíclicos sustituidos de la fórmula (I) o una sal farmacéuticamente aceptable del mismo ESPACIO PARA FÓRMULA activos como inhibidores del canal CFTR, y útiles en el tratamiento de enfermedad poliquística del riñón y diarrea secretora. La presente invención proporciona una composición farmacéutica que comprende una cantidad terapéuticamente efectiva de un compuesto tricíclico heterocíclico sustituido o una sal farmacéuticamente aceptable del mismo, y uno o más vehículos farmacéuticamente aceptables.
CUP2015000066A 2012-12-19 2015-06-19 Compuestos tricíclicos para inhibir el canal cftr CU20150066A7 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261739335P 2012-12-19 2012-12-19
US201361906141P 2013-11-19 2013-11-19
PCT/IB2013/061043 WO2014097148A1 (en) 2012-12-19 2013-12-17 Tricyclic compounds for inhibiting the cftr channel

Publications (1)

Publication Number Publication Date
CU20150066A7 true CU20150066A7 (es) 2015-11-27

Family

ID=50030372

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2015000066A CU20150066A7 (es) 2012-12-19 2015-06-19 Compuestos tricíclicos para inhibir el canal cftr

Country Status (25)

Country Link
US (2) US20140171417A1 (es)
EP (1) EP2935278B1 (es)
JP (1) JP6284546B2 (es)
KR (1) KR20150097660A (es)
CN (1) CN105143230B (es)
AP (1) AP2015008539A0 (es)
AR (1) AR094122A1 (es)
AU (1) AU2013365739A1 (es)
BR (1) BR112015014292A2 (es)
CA (1) CA2895660A1 (es)
CL (1) CL2015001730A1 (es)
CR (1) CR20150325A (es)
CU (1) CU20150066A7 (es)
EA (1) EA201591177A1 (es)
ES (1) ES2628369T3 (es)
HK (1) HK1209741A1 (es)
IL (1) IL239389A0 (es)
MX (1) MX2015007939A (es)
PE (1) PE20151055A1 (es)
PH (1) PH12015501386A1 (es)
SG (1) SG11201504594QA (es)
TN (1) TN2015000279A1 (es)
TW (1) TW201429974A (es)
UY (1) UY35211A (es)
WO (1) WO2014097148A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013038390A1 (en) 2011-09-16 2013-03-21 Novartis Ag N-substituted heterocyclyl carboxamides
AP2015008539A0 (en) 2012-12-19 2015-06-30 Novartis Ag Tricyclic compounds for inhibiting the CFTR channel
US9303035B2 (en) 2012-12-19 2016-04-05 Novartis Ag Substituted pyrazino[1′,2′:1,2]pyrrolo[3,4-d]pyrimidines, pyrimido[4′,5′:3,4]pyrrolo[2,1-c][1,4]oxazines and pyrimido[4′,5′:3,4]pyrrolo[1,2-d][1,4]oxazepines for inhibiting the CFTR channel
JP6695329B2 (ja) 2014-09-19 2020-05-20 モメンティブ パフォーマンス マテリアルズ インコーポレイテッドＭｏｍｅｎｔｉｖｅ Ｐｅｒｆｏｒｍａｎｃｅ Ｍａｔｅｒｉａｌｓ Ｉｎｃ． シロキサンの制御された架橋のための白金（ｉｉ）ジエン錯体
LT3286198T (lt) * 2015-04-23 2021-07-12 Trevi Therapeutics, Inc. Junginiai, skirti gydyti niežulio būkles
CN106478558B (zh) * 2016-10-17 2019-03-29 天津雅奥科技发展有限公司 一种4-羟甲基-二氢-呋喃-2(3h)-酮的合成方法
CN113302192A (zh) 2019-01-17 2021-08-24 豪夫迈·罗氏有限公司 用于制备四氢吡啶并嘧啶的方法
US20220280514A1 (en) * 2019-06-12 2022-09-08 The Regents Of The University Of California Methods of treating bile acid diarrhea
JP2024515828A (ja) 2021-04-29 2024-04-10 ノバルティス アーゲー デユビキチナーゼ標的化キメラ及び関連する方法
CN117654560B (zh) * 2023-12-01 2024-06-04 安徽泽升科技股份有限公司 一种通过氧化氨基连续化制备硝基化合物的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60025616T2 (de) 1999-08-25 2006-11-30 Banyu Pharmaceutical Co., Ltd. Isoindolderivate
JP2002255967A (ja) 2001-02-27 2002-09-11 Banyu Pharmaceut Co Ltd イソインドール誘導体を有効成分とする糖尿病の治療剤、糖尿病の慢性合併症の予防剤又は肥満の治療剤。
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
MX2009006228A (es) 2006-12-12 2009-06-22 Schering Corp Inhibidores de aspartil proteasa.
WO2009042270A2 (en) * 2007-07-05 2009-04-02 Trustees Of Boston University Reca inhibitors and their uses as microbial inhibitors or potentiators of antibiotic activity
JP2011507910A (ja) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
EP2464354B1 (en) 2009-08-10 2015-04-01 The Regents of The University of California Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor
WO2012166658A1 (en) * 2011-05-27 2012-12-06 The Regents Of The University Of California Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
AP2015008539A0 (en) 2012-12-19 2015-06-30 Novartis Ag Tricyclic compounds for inhibiting the CFTR channel
US9303035B2 (en) 2012-12-19 2016-04-05 Novartis Ag Substituted pyrazino[1′,2′:1,2]pyrrolo[3,4-d]pyrimidines, pyrimido[4′,5′:3,4]pyrrolo[2,1-c][1,4]oxazines and pyrimido[4′,5′:3,4]pyrrolo[1,2-d][1,4]oxazepines for inhibiting the CFTR channel

Also Published As

Publication number Publication date
CA2895660A1 (en) 2014-06-26
US20150336986A1 (en) 2015-11-26
IL239389A0 (en) 2015-07-30
JP2016509579A (ja) 2016-03-31
KR20150097660A (ko) 2015-08-26
WO2014097148A1 (en) 2014-06-26
UY35211A (es) 2014-07-31
BR112015014292A2 (pt) 2017-07-11
TW201429974A (zh) 2014-08-01
AU2013365739A1 (en) 2015-07-09
PE20151055A1 (es) 2015-08-05
CN105143230A (zh) 2015-12-09
MX2015007939A (es) 2016-03-11
US9359381B2 (en) 2016-06-07
CL2015001730A1 (es) 2015-08-28
CR20150325A (es) 2015-08-10
ES2628369T3 (es) 2017-08-02
CN105143230B (zh) 2017-06-09
EP2935278B1 (en) 2017-03-15
JP6284546B2 (ja) 2018-02-28
EP2935278A1 (en) 2015-10-28
HK1209741A1 (en) 2016-04-08
AP2015008539A0 (en) 2015-06-30
US20140171417A1 (en) 2014-06-19
PH12015501386A1 (en) 2015-09-02
TN2015000279A1 (en) 2016-10-03
AR094122A1 (es) 2015-07-08
SG11201504594QA (en) 2015-07-30
WO2014097148A9 (en) 2015-02-19
EA201591177A1 (ru) 2015-11-30

Similar Documents

Publication Publication Date Title
CU20150066A7 (es) Compuestos tricíclicos para inhibir el canal cftr
UY39630A (es) Inhibidores de bromodominios
CO2019005165A2 (es) Compuesto de piridona como inhibidor de c-met
CU24397B1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
CR20130487A (es) 1,3-oxazinas como inhibidores de BACE1 y/o BACE2
NI201600058A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
MX2016006336A (es) Compuestos pirazolopirimidina.
CU24350B1 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
DOP2015000201A (es) Compuestos de azabencimidazol como inhibidores de pde4 isoenzimas para el tratamiento del snc y otros trastornos
CR20110634A (es) Inhibidores de fosfoinositida 3 cinasa y/ u objetivo mamifero de rapamicina
CR20140361A (es) Inhibidores de pde9 con estructura básica de imidazotriazinona
MX374513B (es) Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer.
ECSP12011799A (es) Compuestos de espiropiperidina y uso farmacéutico de los mismos
UY32490A (es) Inhibidores de beta-secretasa
UY34960A (es) Dihidropiridona p1 como inhibidores del factor xia
CR20140036A (es) Compuesto inhibidor de la señalización de la trayectoria notch
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
UY35325A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
AR095032A1 (es) Formulaciones de compuestos orgánicos, composición farmacéutica sólida comprimida por rodillo
UY35209A (es) Compuestos tricíclicos